https://faqsir.com/company/mindmaze-therapeutics-holding-sa/feed<![CDATA[MindMaze Therapeutics Holding SA — Announcements]]>MindMaze Therapeutics Holding SA (SIX:MMTX, OTCQB:MMTZF) announcements published on FAQSIR. AI-generated content. Paid-for issuer communication. Not investment advice. Published in partnership with MindMaze Therapeutics Holding SA. MindMaze Therapeutics Holding SA pays FAQSIR a subscription fee for this page.2026-10-14T12:27:33+00:00<![CDATA[MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026]]>https://faqsir.com/3342AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:50+00:002026-10-14T12:26:50+00:00<![CDATA[MindMaze Therapeutics announces planned MindMotion Lite launch by end of 2026]]>https://faqsir.com/3333AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:20+00:002026-10-14T12:26:20+00:00<![CDATA[MindMaze Therapeutics Announces Upcoming Investor and Industry Conference Appearances]]>https://faqsir.com/3334AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:24+00:002026-10-14T12:26:24+00:00<![CDATA[MindMaze Therapeutics Reports H1 2026 Revenue of CHF 0.5 Million and Corporate Update]]>https://faqsir.com/3340AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:42+00:002026-10-14T12:26:42+00:00<![CDATA[MindMaze Therapeutics appoints John Krakauer as strategic advisor]]>https://faqsir.com/3337AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:27+00:002026-10-14T12:26:27+00:00<![CDATA[MindMaze Completes Organisational Simplification and Updates Neuro.io Financing]]>https://faqsir.com/3338AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:38+00:002026-10-14T12:26:38+00:00<![CDATA[MindMaze Reports First SwissNeuroRehab Enrolments and Launch of French Stroke Study]]>https://faqsir.com/3341AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:48+00:002026-10-14T12:26:48+00:00<![CDATA[MindMaze Therapeutics reports AGM outcome as conditional capital proposal fails to secure majority]]>https://faqsir.com/3339AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:41+00:002026-10-14T12:26:41+00:00<![CDATA[MindMaze Therapeutics Publishes Invitation for 2026 Annual General Meeting]]>https://faqsir.com/3336AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:27+00:002026-10-14T12:26:27+00:00<![CDATA[MindMaze Announces RLF-OD032 Rights Sale and Planned Organisational Simplification]]>https://faqsir.com/3335AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:25+00:002026-10-14T12:26:25+00:00<![CDATA[MindMaze Announces CHF 8.0 Million Equity Financing With Neuro.io]]>https://faqsir.com/3350AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:27+00:002026-10-14T12:27:27+00:00<![CDATA[MindMaze Therapeutics and Vibra Healthcare Sign U.S. Neurorehabilitation Partnership]]>https://faqsir.com/3345AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:09+00:002026-10-14T12:27:09+00:00<![CDATA[MindMaze and Vibra Sign Term Sheet for Planned U.S. Go-to-Market Partnership]]>https://faqsir.com/3348AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:19+00:002026-10-14T12:27:19+00:00<![CDATA[MindMaze Therapeutics Publishes 2025 Annual Report and Reports CHF 9.9 Million Net Loss]]>https://faqsir.com/3349AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:19+00:002026-10-14T12:27:19+00:00<![CDATA[MindMaze and Vibra report neurorehabilitation results from two-year programme]]>https://faqsir.com/3344AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:00+00:002026-10-14T12:27:00+00:00<![CDATA[MindMaze Therapeutics Names Zach Henderson CEO as Company Targets U.S. Expansion]]>https://faqsir.com/3343AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:26:50+00:002026-10-14T12:26:50+00:00<![CDATA[MindMaze Therapeutics outlines post-listing plans and publishes March 2026 presentation]]>https://faqsir.com/3347AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:18+00:002026-10-14T12:27:18+00:00<![CDATA[MindMaze Therapeutics outlines reimbursement strategy across US, Switzerland and UK]]>https://faqsir.com/3351AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:33+00:002026-10-14T12:27:33+00:00<![CDATA[MindMaze Therapeutics completes NeuroX business combination]]>https://faqsir.com/3346AI-generated content. Paid-for issuer communication. Not investment advice.2026-10-14T12:27:11+00:002026-10-14T12:27:11+00:00